ALB and COVID-19: With the proposed XGB method, the predictive factors linked to a poorer outcome in COVID-19 patients treated with remdesivir, in terms of mortality, include limitation of life support treatment, a need for ventilatory support (especially IMV) on day 14 after the first dose of remdesivir, lymphopenia, low levels of albumin and hemoglobin, the presence of flu and/or coinfection, and cough.